DxPx: The First International Diagnostics Partnering Conference

DUSSELDORF, Germany – Diagnostics is one of the fastest growing medical disciplines. Therefore it has been only a matter of time for a fair to focus exclusively on this important topic: DxPx Conference, which will take place for the first time on November 18, 2019 in Dusseldorf, Germany (Maritim Hotel), is the first international partnering conference focusing exclusively on the diagnostics and research tool industry. The event targets established companies, start-ups and investors and will from now on take place every year on the opening day of MEDICA to also attract Asian and US participants.

“New and improved diagnostic methods can help patients avoid those endless medical appointment odysseys. They form the basis for efficient individualized treatments. DxPx Conference honors the growing importance of this discipline by creating a platform for international cooperation”, says Dr. Mirko Stange, CEO of Silversky LifeScience GmbH, the initator and organizer of DxPx Conference. “We are excited to have Roche Diagnostics, Sonic Healthcare’s Bioscientia, and the Business Intelligence provider Research Analytica as our first strong partners. We are also talking to additional well-known sponsors from China and the US and we are convinced that together with our partners we will make the DxPx premiere a success for all parties involved.”

Startups can apply for free participation in DxPx and one of 15 DxPx presentation slots for showcasing their ideas and products to the international DxPx audience by submitting a short business plan in the conference’s run-up. DxPx sponsors and selected industry experts will act as the jury for selecting the presenting start-ups on the basis of their applications. Interested companies can upload their business plan on www.dxpx-conference.com. “We want to promote intensive dialogue between the industry’s newcomers, established players, and fair visitors, and we are looking forward to receiving widely divers applications”, says Mirko Stange. Dr. Peter Wieloch, Head of Bioscientia’s diagnostics2market outlines: “As Europe’s leading lab diagnostic services provider and part of the Australian Sonic Healthcare Group we constantly evaluate partnering options with new diagnostics providers.” Prof. Dr. Wolfgang Kaminski, CMO of Sonic Healthcare Germany adds: “We are always looking for real medical progress to help us further increase the quality of our lab services. We consider DxPx conference a suitable platform for efficiently exchanging insights on management level.”

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.


Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.


John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.


Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.


FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.